Symbol="INO"
AssetType="Common Stock"
Name="Inovio Pharmaceuticals Inc"
Description="Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases associated with the human papillomavirus (HPV), cancer, and infectious diseases. "
CIK="1055726"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="SURGICAL & MEDICAL INSTRUMENTS & APPARATUS"
Address="6769 MESA RIDGE RD., SAN DIEGO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="137702000"
EBITDA="-235906192"
PERatio="None"
PEGRatio="0"
BookValue="0.758"
DividendPerShare="0"
DividendYield="0"
EPS="-1.01"
RevenuePerShareTTM="0.041"
ProfitMargin="0"
OperatingMarginTTM="-23.56"
ReturnOnAssetsTTM="-0.421"
ReturnOnEquityTTM="-0.871"
RevenueTTM="10178100"
GrossProfitTTM="-177388235"
DilutedEPSTTM="-1.01"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.423"
AnalystTargetPrice="1.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="40.0"
PriceToBookRatio="1.721"
EVToRevenue="19.1"
EVToEBITDA="-0.649"
Beta="0.964"
num_52WeekHigh="2.82"
num_52WeekLow="0.38"
num_50DayMovingAverage="0.535"
num_200DayMovingAverage="1.242"
SharesOutstanding="262740000"
DividendDate="None"
ExDividendDate="None"
symbol="INO"
open="0.51"
high="0.53"
low="0.50"
price="0.52"
volume="2010978.00"
latest_trading_day="2023-07-28"
previous_close="0.50"
change="0.02"
change_percent="4.4856%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="7904430"
Change_recent_avg="-0.01"
Delta_recent_avg="0.06"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-1.18"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="166"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0010.jpeg"
image_negative_thumbnail_id_2="493"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0112.jpeg"
image_neutral_thumbnail_id_1="563"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0036.jpeg"
image_neutral_thumbnail_id_2="568"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0031.jpeg"
image_positive_thumbnail_id_1="1166"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Negative_0187.jpeg"
image_positive_thumbnail_id_2="702"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0006.jpeg"
image_professor_thumbnail_id_1="1184"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
image_professor_thumbnail_id_2="1202"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0036.jpeg"
